Tweet Tolebrutinib which is a irreversible BTK inhibitor was shown in a trial to inhibit non-relapsing progressive MS, but development has been held up in US because of liver damage signals. Results from the HERCULES phase 3 study showed delay in disability progression in people…
Multiple Sclerosis explores the new pavillion Turns out, I AM a Barbie girl. If Barbie was a perpetually confused, middle aged woman with a slight attitude, MS, and a ton of fatigue. And sneakers. None of those little, pink, plastic heals for me, thank you…
First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple sclerosis (RRMS) over six years, according to data from a Phase 3b clinical trial and its extension study. The findings were presented in a talk by Robert…
I had never known anyone personally who had been admitted to a psychiatric hospital. Walking my husband, Rhead, through those doors was one of the strangest moments of my life — not strange in a dramatic way, but strange in the quiet, disorienting way of…
I have realized that every time I go to a doctor’s appointment, I walk in already feeling guilty — mentally preparing to defend myself, almost expecting judgment. Before the doctor starts asking about my exercise routines and eating habits, I … Continue reading → Source:…
Tweet So it looks like Fenebrutinib may make it where other BTK inhibiotrs has so far failed. The drug inibits relapsing and primary progressive MS in regard to primary progressive MS it is no worse than ocrelizumab and make be a little better. The main…
There are moments when living with Multiple Sclerosis feels like a series of calculations between what we can afford, what can wait, and what simply cannot happen at all. Dan recently faced one of those moments when he needed hernia surgery. It wasn’t optional, and…
Tweet Frexalimab is an indirect B cell inhibitor. It block the natural signal that a B cell gets from T cells and antigen presenting cells as it blocks the ligand (binding bit) to the CD40 receptor. This receptor needs to be stumulated at the same…
Tweet We recently had a post where the FDA was starting to question the data from the ORATORIO trial and British Medical Journal suggested that the data was fudged and that the women in the trial got no/less efficacy and that they got a risk…
Patient enrollment is complete in a Phase 3 trial testing a new formulation of Briumvi (ublituximab-xiiy), TG Therapeutics‘ multiple sclerosis (MS) medication for relapsing forms of the disease, that could be injected at home. The new formulation is designed to be given under the skin, or…